Mabwell(688062) 证券之星·2025-03-30 10:17Meeting Overview - The second session of the Supervisory Board of Maiwei (Shanghai) Biotechnology Co., Ltd. was held on March 30, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the 2024 Annual Report and its summary, affirming that the report accurately reflects the company's financial status and operational results without any misleading statements or omissions [2]. - The 2025 Financial Budget Report was also approved, pending review at the 2024 Annual General Meeting [2]. - The 2024 Financial Settlement Report received approval, also subject to the upcoming shareholder meeting [2]. - A special report on the storage and actual use of funds raised in 2024 was approved, confirming compliance with relevant regulations and proper use of funds [2][3]. - The 2024 Internal Control Evaluation Report was approved, indicating effective internal control execution without significant defects [3]. - The profit distribution plan for 2024 was approved, pending shareholder review [4]. - The reappointment of Ernst & Young Hua Ming as the auditing firm for 2025 was approved, ensuring compliance with legal and regulatory requirements [4]. - The 2025 Employee Compensation Plan was approved, aimed at enhancing management levels and motivating employees [5]. - The proposal for the company and its subsidiaries to apply for credit limits from financial institutions was approved, aligning with business needs [5][6]. - The proposal for the use of surplus funds from completed fundraising projects to supplement working capital was approved, enhancing fund utilization efficiency [6][7].